Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug;100(8):1921-1927.
doi: 10.1007/s00277-021-04532-w. Epub 2021 Jun 14.

Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia

Affiliations

Association of KLOTHO polymorphisms with clinical complications of sickle cell anemia

Jéssica V G F Batista et al. Ann Hematol. 2021 Aug.

Abstract

The clinical and phenotypic heterogeneity of patients with sickle cell anemia (SCA) is influenced by environmental and genetic factors. Several genetic modifiers, such as the KLOTHO (KL) gene, have been associated with SCA clinical outcomes. The KL gene and its encoded proteins are implicated in important biological pathways, which affect the disease's pathophysiology, such as expression of adhesion molecules VCAM-1 and ICAM-1, oxidative stress, and nitric oxide biology. Here, we evaluated the clinical relevance of two polymorphisms found on the KL gene (rs685417 and rs211239) in 588 unrelated patients with SCA. Genotyping analyses were performed using the TaqMan system. The KL rs211239 was associated with increased number of vaso-occlusive crisis (VOCs) per year (P = 0.001), while KL rs685417 was associated with increased frequency of stroke (P = 0.034), priapism (P = 0.011), number of complications (P = 0.019), and with a lower incidence of priapism (P = 0.036). Additionally, the associations with VOCs, stroke, and priapism remained consistent in multivariate analyses (P < 0.05). Our data highlight the clinical importance of KL in SCA.

Keywords: Clinical outcome; KL rs211239; KL rs685417; Prognostic markers; Sickle cell disease.

PubMed Disclaimer

References

    1. Sommer CK, Goldbeck AS, Wagner SC, Castro SM (2006) Triagem neonatal para hemoglobinopatias: experiência de um ano na rede de saúde pública do Rio Grande do Sul, Brasil. Cad Saude Publica 22(8):1709–1714 - DOI
    1. Simões BP, Pieroni F, Barros GMN, Machado CL, Cançado RD, Salvino MA, Angulo I, Voltarelli JC (2010) Consenso brasileiro em transplante de células-tronco hematopoéticas: comitê de hemoglobinopatias. Rev Bras Hematol Hemoter 32:46–53. https://doi.org/10.1590/S1516-84842010005000020 - DOI
    1. Sebastiani P, Solovieff N, Hartley SW, Milton JN, Riva A, Dworkis DA, Melista E, Klings ES, Garrett ME, Telen MJ, Ashley-Koch A, Baldwin CT, Steinberg MH (2010) Genetic modifiers of the severity of sickle cell anemia identified through a genome-wide association study. Am J Hematol 85(1):29–35. https://doi.org/10.1002/ajh.21572.Genetic - DOI - PubMed - PMC
    1. Saito Y, Yamagishi T, Nakamura T, Ohyama Y, Aizawa H, Suga T, Matsumura Y, Masuda H, Kurabayashi M, Kuro-o M, Nabeshima YI, Nagai R (1998) Klotho protein protects against endothelial dysfunction. Biochem Biophys Res Commun 248:324–329 - DOI
    1. Maekawa Y, Ishikawa K, Yasuda O, Oguro R, Hanasaki H, Kida I, Takemura Y, Ohishi M, Katsuya T, Rakugi H (2009) Klotho suppresses TNF-α-induced expression of adhesion molecules in the endothelium and attenuates NF-κB activation. Endocr. 35:341–346. https://doi.org/10.1007/s12020-009-9181-3 - DOI

LinkOut - more resources